| Schedule of Reconciliation Consolidated Net Loss |
The
following table presents certain financial data for the Company’s two reportable segments and a reconciliation to the Company’s
consolidated net loss.
Schedule
of Reconciliation Consolidated Net Loss
| |
|
|
2026 |
|
|
|
2025 |
|
|
|
2026 |
|
|
|
2025 |
|
| |
|
|
For the Three Months Ended
September 30,
|
|
|
|
For the Nine Months Ended
September 30,
|
|
| |
|
|
2026 |
|
|
|
2025 |
|
|
|
2026 |
|
|
|
2025 |
|
| Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Computing
Technology |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Total
Sales |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Product
Cost of Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Computing
Technology |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Total
Cost of Sales |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Gross
Profit |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating
Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Administrative
Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
109,757 |
|
|
|
967,833 |
|
|
|
363,001 |
|
|
|
2,703,815 |
|
| Computing
Technology |
|
|
987,815 |
|
|
|
- |
|
|
|
3,267,012 |
|
|
|
- |
|
| Total
Administrative Expenses |
|
|
1,097,572 |
|
|
|
967,833 |
|
|
|
3,630,013 |
|
|
|
2,703,815 |
|
| Research
and Development Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
4,074 |
|
|
|
356,352 |
|
|
|
28,172 |
|
|
|
2,775,337 |
|
| Computing
Technology |
|
|
379,308 |
|
|
|
- |
|
|
|
1,101,877 |
|
|
|
- |
|
| Total
Research and Development Expenses |
|
|
383,382 |
|
|
|
356,352 |
|
|
|
1,130,049 |
|
|
|
2,775,337 |
|
| Stock
Based Compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
189,490 |
|
| Computing
Technology |
|
|
860,667 |
|
|
|
- |
|
|
|
5,343,060 |
|
|
|
- |
|
| Total
Stock Based Compensation |
|
|
860,667 |
|
|
|
- |
|
|
|
5,343,060 |
|
|
|
189,490 |
|
| Franchise
Tax Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
12,365 |
|
|
|
200,050 |
|
|
|
34,306 |
|
|
|
200,050 |
|
| Computing
Technology |
|
|
111,289 |
|
|
|
- |
|
|
|
308,751 |
|
|
|
- |
|
| Total
Franchise Tax Expense |
|
|
123,654 |
|
|
|
200,050 |
|
|
|
343,057 |
|
|
|
200,050 |
|
| Warrant
Issuance Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
-
|
|
|
|
264,417 |
|
|
|
- |
|
|
|
264,417 |
|
| Computing
Technology |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Total
Warrant Issuance Expenses |
|
|
- |
|
|
|
264,417 |
|
|
|
- |
|
|
|
264,417 |
|
| Transaction
costs associated with due diligence |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Computing
Technology |
|
|
100,000 |
|
|
|
- |
|
|
|
100,000 |
|
|
|
- |
|
| Total
Transaction costs associated with due diligence |
|
|
100,000 |
|
|
|
- |
|
|
|
100,000 |
|
|
|
- |
|
| Segment Net Loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
126,196 |
|
|
|
1,788,652 |
|
|
|
425,479 |
|
|
|
6,133,109 |
|
| Computing
Technology |
|
|
2,439,079 |
|
|
|
- |
|
|
|
10,120,700 |
|
|
|
- |
|
| Total
Segment Net Loss |
|
|
2,565,275 |
|
|
|
1,788,652 |
|
|
|
10,546,179 |
|
|
|
6,133,109 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reconcilement
of Net Loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adjustments
and Reconciling Items |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest
and Dividend Income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
35,955 |
|
|
|
- |
|
|
|
156,042 |
|
| Computing
Technology |
|
|
55,477 |
|
|
|
- |
|
|
|
227,442 |
|
|
|
- |
|
| Total
Interest and Dividend Income |
|
|
55,477 |
|
|
|
35,955 |
|
|
|
227,442 |
|
|
|
156,042 |
|
| Gain
(Loss) on Sales of Marketable Securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
2,176 |
|
| Computing
Technology |
|
|
24,410 |
|
|
|
- |
|
|
|
55,651 |
|
|
|
- |
|
| Total
Gain (Loss) on Sales of Marketable Securities |
|
|
24,410 |
|
|
|
- |
|
|
|
55,651 |
|
|
|
2,176 |
|
| Unrealized
Gain (Loss) on Marketable Securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
309 |
|
|
|
- |
|
|
|
(1,435 |
)- |
| Computing
Technology |
|
|
2,595 |
|
|
|
- |
|
|
|
(4,695 |
) |
|
|
- |
|
| Total
Unrealized Gain (Loss) on Marketable Securities |
|
|
2,595 |
|
|
|
309 |
|
|
|
(4,695 |
) |
|
|
(1,435 |
)- |
| Change
in Fair Value of Derivative Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
(1,059,000 |
) |
|
|
- |
|
|
|
244,000 |
|
| Computing
Technology |
|
|
1,541,000 |
|
|
|
- |
|
|
|
2,132,000 |
|
|
|
- |
|
| Total
Change in Fair Value of Derivative Liabilities |
|
|
1,541,000 |
|
|
|
(1,059,000 |
) |
|
|
2,132,000 |
|
|
|
244,000 |
|
| Impairment
of Technology License |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Computing
Technology |
|
|
- |
|
|
|
- |
|
|
|
(3,177,999 |
) |
|
|
- |
|
| Total
Impairment of Technology License |
|
|
- |
|
|
|
- |
|
|
|
(3,177,999 |
) |
|
|
- |
|
| Total
Adjustments and Reconciling Items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
(1,022,736 |
)- |
|
|
- |
|
|
|
400,783- |
|
| Computing
Technology |
|
|
1,623,482 |
|
|
|
- |
|
|
|
(767,601 |
) |
|
|
- |
|
| Total
Adjustments and Reconciling Items |
|
|
1,623,482 |
|
|
|
(1,022,736 |
)- |
|
|
(767,601 |
) |
|
|
400,783- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Consolidated
Net Loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
(126,196 |
) |
|
|
(2,811,388 |
) |
|
|
(425,479 |
) |
|
|
(5,732,326 |
) |
| Computing
Technology |
|
|
(815,597 |
) |
|
|
- |
|
|
|
(10,888,301 |
) |
|
|
- |
|
| Consolidated
Net Loss |
|
|
(941,793 |
) |
|
|
(2,811,388 |
) |
|
|
(11,313,780 |
) |
|
|
(5,732,326 |
) |
|